6th International Conference on
Drug Delivery and Formulations

Biography:

Dr. Pavitra has his expertise in pharmaceutical nanotechnology and drug evaluation in improving the women health and wellbeing. His pharmacodynamic and pharmacokinetic evaluation model based on osteoporotic wistar rats for improving osteoporotic related disorders is commendable. He has gained this after years of experience in animal model research, drug evaluation, teaching and administration both in research and educational institutions. He has published more than 20 research papers and received national as well as international awards in drug delivery and nanotechnological based research

Abstract:

Statement of the Problem: Osteoporosis emerged as a chronic disease of skeleton system leading to weaken bones and hip fractures making it a burden to the society. During lifetime, one out of every three women and one out of every six males will experience an osteoporotic fracture. Every minute, eight new fracture cases are reported in the EU. In the European Union, it is projected that over 23 million men and women are at high risk of osteoporotic fractures. According to estimates from 2019, osteoporosis and the 4.3 million fragility fractures it generates cost Europe's health-care systems more than €56 billion every year.  Methodology: A nano complex tagged pamidronate was prepared with hot-micro-emulsification and ultrasonication method. The prepared formulation was characterized for particle size, zeta potential, in-vitro drug release, ex-vivo gut permeation and in-vivo anti osteoporosis activity. Size of nanoformulation was further confirmed by TEM. Bone mineral density of wistar rat femur was determined using micro-computed tomography and bone mechanical strength was determined with universal testing machine. Clinical findings: The oral bioavailability and permeability was enhanced by 37.56 % and 152.71% respectively. Bone mineral density was enhanced in female wistar rat models by 25.81 % compared to marketed formulation. Bone strength was enhanced by 19.22 % Conclusion & Significance: Bisphosphonates are the primary therapeutic agents for treating osteoporosis but very low oral bioavailability limits their use. In this paper, a novel approach was utilized to develop orally applicable nanoformulation with significant oral bioavailability to reduce injection and cost burden to the society. This research will be of great interest in further studies with significant outcomes to treat post-menopausal osteoporosis in women.